Let’s start with the bad news… we got quarterly updates this week from Charlotte’s Web (CWEB.TO, CWBHF) and II-VI (IIVI), both stocks I’ve bought fairly recently (IIVI just a few weeks ago, CWEB a few months ago), and those are both in the red. Neither one hit a stop loss yet, but what did we […]
Earnings season is clobbering me with news once again this week, so there’s a lot to share… I’ll start with the actual transactions I made today, and move on to look at a dozen other stocks I own or am watching… buckle up! We’ll start with the one that probably most of you can’t easily […]
A pretty quiet week as I try not to overreact to market gyrations, so we’ll be briefer than usual this Friday… but there are a few interesting things to talk about…. Crown Castle (CCI) reported a “beat and raise” quarter this week, if just barely. They raised their dividend roughly as expected this week, bumping […]
Dave Lashmet has been a biotech/medical analyst and sometimes a newsletter editor at Stansberry for a long time, and the latest iteration of his high-end newsletter is now called Stansberry Venture Technology (currently “on sale” for $2,500, no refunds)… and it’s now being promoted with a “cure for cancer” spiel, so we obviously all want […]
We have a couple traditions here at Stock Gumshoe… we call out one of the worst teaser stock ideas around Thanksgiving and identify the “Turkey of the Year,” and then, as the year comes to a close and holiday merriment washes all around us, we call attention to the best teaser stocks of the year. […]
Andrew Snyder has been on the editorial team of a bunch of different Agora-affiliated newsletters over the years, and is now helming his own little offshoot called Manward Press — a publishing imprint that aims to helm men reach “true fulfillment” by focusing on “Liberty, Know-how and connections” … though, of course, to sell newsletters […]
Lots and lots and lots of you have been asking me about the big “cancer presentation” that the Stansberry folks made last night, which apparently was a combination of Dr. David Eifrig’s medical advice and forecasting and Dave Lashmet’s hinting about his “medical breakthrough” stock… so let’s get to it. I did not watch or […]
Comments
Trade Note: I hit my stop loss with Hershey (HSY), so those shares are sold. I wouldn't be against ...
Oh, and yes, it turns out that long Elekta/short ViewRay would have been the right call -- VRAY is down 23% at the momen...
Elekta not doing so bad for that first six months since Lashmet teased it (assuming the Thinkolator was right on this on...